A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2140-2145

  Cattaneo, Chiara ^a   Monte, Simona ^a   Algarotti, Alessandra ^b   Audisio, Ernesta ^c   Borlenghi, Erika ^a   Campiotti, Leonardo ^d   Cerqui, Elisa ^a   Fanizza, Caterina ^a   Giuliani, Rachele ^a   Micò, Caterina ^b   Rocconi, Roberta ^e   Salvi, Anna ^b   Salvi, Flavia ^f   Verga, Luisa ^g   Levis, Alessandro ^f   Deliliers, Giorgio Lambertenghi ^h   Pogliani, Enrico M ^g   Tognoni, Gianni ^a   Rambaldi, Alessandro ^b   Rossi, Giuseppe ^a  

^a Spedali Civili ^*  (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e Ospedale Umberto I   (Italy)

^f C Arrigo Children's Hospital   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Echinocandins; IFIs; Invasive fungal infections

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CASPOFUNGIN; CYTARABINE; FLUCONAZOLE; IDARUBICIN; ITRACONAZOLE; LEVOFLOXACIN; POSACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLUS; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CANDIDA; CANDIDEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIPODASCUS CAPITATUS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FUNGEMIA; HEALTH CARE POLICY; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; PARANASAL SINUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN TOXICITY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; COHORT STUDIES; ECHINOCANDINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PULMONARY ASPERGILLOSIS; SAMPLE SIZE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051687815     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr271     Document Type: Article

References (24)

1. Bow E. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 2008; 140: 133-52.
2. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
3. Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 1: 5471-89.
4. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
5. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862-70.
6. Borlenghi E, Cattaneo C, Capucci MA et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol 2007; 86: 205-10.
7. Maertens JA, Frere P, Lass-Florl C et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007; S5: 43-8.
8. Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-22.
9. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-84.
10. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43 Suppl 1: S3-14.
11. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin vs liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
12. Chou LS, Lewis RE, Ippoliti C et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644-50.
13. Bassan R, Spinelli O, Oldani E et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153-62.
14. Bassan R, Intermesoli T, Masciulli A et al. Pediatric-type therapy including lineage-targeted methotrexate to improve early minimal residual disease response and survival in adult acute lymphoblastic leukemia (ALL): interim analysis of Northern Italy Leukemia Group study 10/07. In: Abstracts of the Fifty-second ASH Annual Meeting, Orlando, FL, 2010. Abstract 2131. American Society of Hematology, USA.
15. Intermesoli T, Oldani E, Rossi G et al. Two-step response-oriented induction predicts long-term outcome of adult patients with standard- and high-risk acute myeloid leukaemia (AML): a Northern Italy Leukaemia Group (NILG) study. In: Abstracts of the Fifteenth EHA Annual Meeting, Barcelona, 2010. Abstract 649. European Hematology Association.
16. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
17. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
18. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematological malignancies. Eur J Haematol 2007; 78: 275-82.
19. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011; 46: 709-18.
20. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
21. De Pauw B, Rubin RH. Prophylaxis and aspergillosis-has the principle been proven? N Engl J Med 2007; 356: 409-11.
22. Marr KA, Laverdiere M, Gugel A et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-9.
23. Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and the relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
24. Matiuzzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-7.